Inventor · disambiguated record
Xingyue He
Also filed as: HE XINGYUE
3 granted patents·7 pending applications·8 citations·filing 2008–2025
60Inventor score
Files withMEMORIAL SLOAN KETTERING CANCER CENTER3TAKEDA PHARMACEUTICALS CO3AFFINI T THERAPEUTICS INC2CLEARY MICHELE A1HE LIN1
Top patents by PatentIndex Score
10 records- 0178US9132152B2Compositions and methods for generating induced pluripotent stem cellsHE LIN·Filed 2012·Granted Sep 15, 2015·3 cites·28 claims
- 0278US8399248B2Methods of using MIR34 as a biomarker for TP53 functional statusCLEARY MICHELE A·Filed 2008·Granted Mar 19, 2013·5 cites·14 claims
- 0362US12331129B2Chimeric receptors targeting ADGRE2 and/or CLEC12A and uses thereofMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2022·Granted Jun 17, 2025·0 cites·66 claims
- 0461US2025152717A1Binding proteins and engineered cells specific for neoantigens and uses thereofAFFINI T THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0560US2025250356A1Chimeric receptors targeting adgre2 and/or clec12a and uses thereofMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2025·Application pending·0 cites
- 0657US2023346938A1Chimeric antigen receptors targeting cd19 and use thereofMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2022·Application pending·0 cites
- 0754US2024033359A1Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereofTAKEDA PHARMACEUTICALS CO·Filed 2021·Application pending·0 cites
- 0852US2024050473A1Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereofTAKEDA PHARMACEUTICALS CO·Filed 2021·Application pending·0 cites
- 0952US2024374721A1Car-expressing immune cells that specifically target mesothelin and uses thereofTAKEDA PHARMACEUTICALS CO·Filed 2022·Application pending·0 cites
- 1043US2025281614A1Chimeric receptors comprising interleukin 7 receptor (il7r) domainsAFFINI T THERAPEUTICS INC·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Xingyue He files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →